Scientists from Rice University announced the first direct observation of a phenomenon called a superradiant phase transition ...

In a groundbreaking discovery, a team of researchers at the Rice University have reported the first direct observation of a ...

The past six months haven’t been great for Sarepta Therapeutics. It just made a new 52-week low of $52, and shareholders have ...

Fintel reports that on April 11, 2025, Wells Fargo initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a ...

Sarepta Therapeutics (NASDAQ:SRPT) stock draws an Overweight rating at Wells Fargo, based on commercial prospects for ...

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian Abrahams downgraded the stock from a Buy to a Hold rating and slashed the price ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( is currently investigating potential violations of the federal ...

Morgan Stanley analyst Michael Ulz maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

Wells Fargo initiated coverage of Sarepta (SRPT) with an Overweight rating and $115 price target Despite the recent Gr5 AE case, the firm ...

A team of Rice researchers reported the first direct observation of a surprising quantum phenomenon predicted over half a ...

More than 800 people have been treated with Elevidys, the only approved treatment for Duchenne muscular dystrophy, the company said.

Fintel reports that on April 11, 2025, Wells Fargo initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a Overweight recommendation. As of April 1, 2025, the average one-year price ...